Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention

References

• Products - vital statistics rapid release - provisional drug overdose data [Internet]. 2023 [accessed 2023 Aug 9]. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
   Google Scholar
• De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy. 2010;21:364–80. doi:10.1016/j.drugpo.2010.01.010.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns of opioid use and dependence: population harms, interventions, and future action. Lancet Lond Engl. 2019;394:1560–79. doi:10.1016/S0140-6736(19)32229-9.
   PubMed Web of Science ®Google Scholar
• Williams AR, Johnson KA, Thomas CP, Reif S, Socías ME, Henry BF, Neighbors C, Gordon AJ, Horgan C, Nosyk B, et al. Commentary article: opioid use disorder cascade of care framework design: a roadmap. Subst Abuse. 2022;43:1207–14. doi:10.1080/08897077.2022.2074604.
   PubMed Web of Science ®Google Scholar
• Williams AR, Mauro CM, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, Samples H, Chiodo L. Performance measurement for opioid use disorder medication treatment and care retention. Am J Psychiatry. 2023;180:454. doi:10.1176/appi.ajp.20220456.
   PubMed Web of Science ®Google Scholar
• Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and Hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med Malden Mass. 2010;11:1092–98. doi:10.1111/j.1526-4637.2010.00881.x.
   PubMed Web of Science ®Google Scholar
• Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry. 2020;87:44–53. doi:10.1016/j.biopsych.2019.05.023.
   PubMed Web of Science ®Google Scholar
• Vuong C, Van Uum SHM, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132. doi:10.1210/er.2009-0009.
   PubMed Web of Science ®Google Scholar
• Fountas A, Chai ST, Kourkouti C, Karavitaki N. Mechanisms of endocrinology: endocrinology of opioids. Eur J Endocrinol. 2018;179:R183–96. doi:10.1530/EJE-18-0270.
   PubMed Web of Science ®Google Scholar
• de Vries F, Bruin M, Lobatto DJ, Dekkers OM, Schoones JW, van Furth WR, Pereira AM, Karavitaki N, Biermasz NR, Zamanipoor Najafabadi AH. Opioids and their endocrine effects: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105:1020–29. doi:10.1210/clinem/dgz022.
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009;32:131–39. doi:10.1111/j.1365-2605.2007.00824.x.
   PubMed Web of Science ®Google Scholar
• Yee A, Loh HS, Danaee M, Riahi S, Ng CG, Sulaiman AH. Plasma testosterone and sexual function in Southeast Asian men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2018;15:159–66. doi:10.1016/j.jsxm.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8:1598–605. doi:10.1111/andr.12867.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44. doi:10.1210/jc.2018-00229.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Billeci D, Maggi M, Corona G. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest. 2018;41:1377–88. doi:10.1007/s40618-018-0964-3.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8:970–87. doi:10.1111/andr.12770.
   PubMed Web of Science ®Google Scholar
• Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E . The association of hypogonadism with depression and its treatments. Front Endocrinol (Lausanne). 2023;14:1198437. doi:10.3389/fendo.2023.1198437.
   PubMed Web of Science ®Google Scholar
• Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry. 2005;66:7–14. doi:10.4088/JCP.v66n0102.
   PubMed Web of Science ®Google Scholar
• Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35. doi:10.1056/NEJMoa0911101.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Archives Int Med. 2006;166(4):465–71. doi:10.1001/.465.
   PubMedGoogle Scholar
• Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2011;19:274–83. doi:10.1097/JGP.0b013e3181e70c22.
   PubMed Web of Science ®Google Scholar
• Hunt GE, Malhi GS, Cleary M, Lai HMX, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: systematic review and meta-analysis. J Affect Disord. 2016;206:331–49. doi:10.1016/j.jad.2016.07.011.
   PubMed Web of Science ®Google Scholar
• Saha S, Lim CC, Degenhardt L, Cannon DL, Bremner M, Prentis F, Lawrence Z, Heffernan E, Meurk C, Reilly J, et al. Comorbidity between mood and substance-related disorders: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2022;56:757–70. doi:10.1177/00048674211054740.
   PubMed Web of Science ®Google Scholar
• Crum RM, Green KM, Amin-Esmaeili M, Susukida R, Mojtabai R, Storr CL, Riehm KE, Young AS, Reboussin BA. The role of mood disorders in the progression of and recovery from alcohol and drug use problems: a latent transition analysis. Drug Alcohol Depend. 2022;238:109566. doi:10.1016/j.drugalcdep.2022.109566.
   PubMed Web of Science ®Google Scholar
• Esmaeelzadeh S, Moraros J, Thorpe L, Bird Y. Examining the association and directionality between mental health disorders and substance use among adolescents and young adults in the U.S. and Canada—A systematic review and meta-analysis. J Clin Med. 2018;7:543. doi:10.3390/jcm7120543.
   PubMed Web of Science ®Google Scholar
• McGrath JJ, Lim CCW, Plana-Ripoll O, Holtz Y, Agerbo E, Momen NC, Mortensen PB, Pedersen CB, Abdulmalik J, Aguilar-Gaxiola S, et al. Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries. Epidemiol Psychiatr Sci. 2020;29:e153. doi:10.1017/S2045796020000633.
   PubMed Web of Science ®Google Scholar
• Greiner MG, Shulman M, Scodes J, Choo TH, Pavlicova M, Opara O, Campbell ANC, Novo P, Fishman M, Lee JD, et al. Patient characteristics associated with opioid abstinence after participation in a trial of buprenorphine versus injectable naltrexone. Subst Use Misuse. 2022;57:1732–42.
   PubMed Web of Science ®Google Scholar
• Hasin D, Liu X, Nunes E, McCloud S, Samet S, Endicott J. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002;59:375–80. doi:10.1001/archpsyc.59.4.375.
   PubMed Web of Science ®Google Scholar
• Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addict Abingdon Engl. 2013;108:115–23. doi:10.1111/j.1360-0443.2012.04010.x.
   PubMed Web of Science ®Google Scholar
• Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2014;26:19–32.
   Google Scholar
• Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, Kotb A, Skidmore B, Bai Z, Mamdani M, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7:e015284.
   PubMed Web of Science ®Google Scholar
• Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiarty. 2019;76:31–40. doi:10.1001/jamapsychiatry.2018.2734.
   PubMed Web of Science ®Google Scholar
• Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15:289. doi:10.1097/01.pra.0000358315.88931.fc.
   PubMed Web of Science ®Google Scholar
• Athnaiel O, Cantillo S, Paredes S, Knezevic NN. The role of sex hormones in pain-related conditions. Int J Mol Sci. 2023;24:1866. doi:10.3390/ijms24031866.
   PubMedGoogle Scholar
• Maurer AJ, Lissounov A, Knezevic I, Candido KD, Knezevic NN. Pain and sex hormones: a review of current understanding. Pain Manag. 2016;6:285–96. doi:10.2217/pmt-2015-0002.
   PubMed Web of Science ®Google Scholar
• Chen SC, Chang TJ, Wu FS. Competitive inhibition of the capsaicin receptor-mediated current by dehydroepiandrosterone in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 2004;311:529–36. doi:10.1124/jpet.104.069096.
   PubMed Web of Science ®Google Scholar
• Craft RM. Modulation of pain by estrogens. PAIN. 2007 Nov;132:S3. doi:10.1016/j.pain.2007.09.028.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–18. doi:10.1210/jc.2003-031069.
   PubMed Web of Science ®Google Scholar
• Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab. 2006;91:546–54. doi:10.1210/jc.2005-1664.
   PubMed Web of Science ®Google Scholar
• Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addict Abingdon Engl. 2007;102:752–60. doi:10.1111/j.1360-0443.2007.01759.x.
   PubMed Web of Science ®Google Scholar
• Compton PA, Wasser TE, Cheatle MD. Increased experimental pain sensitivity in chronic pain patients who developed opioid use disorder. Clin J Pain. 2020;36:667–74. doi:10.1097/AJP.0000000000000855.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Vaegter HB, Christensen LL, Bendix E, Graven-Nielsen T, Andersen PG, Andersen M. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial. Eur J Endocrinol. 2020;182:539–48. doi:10.1530/EJE-19-0979.
   PubMed Web of Science ®Google Scholar
• Grönbladh A, Nylander E, Hallberg M. The neurobiology and addiction potential of anabolic androgenic steroids and the effects of growth hormone. Brain Res Bull. 2016;126:127–37. doi:10.1016/j.brainresbull.2016.05.003.
   PubMed Web of Science ®Google Scholar
• Johnson LR, Wood RI. Oral testosterone self-administration in male hamsters. Neuroendocrinology. 2001;73:285–92. doi:10.1159/000054645.
   PubMed Web of Science ®Google Scholar
• Parrilla-Carrero J, Figueroa O, Lugo A, García-Sosa R, Brito-Vargas P, Cruz B, Rivera M, Barreto-Estrada JL. The anabolic steroids testosterone propionate and nandrolone, but not 17α-methyltestosterone, induce conditioned place preference in adult mice. Drug Alcohol Depend. 2009;100:122–27. doi:10.1016/j.drugalcdep.2008.09.014.
   PubMed Web of Science ®Google Scholar
• Wood RI, Johnson LR, Chu L, Schad C, Self DW. Testosterone reinforcement: intravenous and intracerebroventricular self-administration in male rats and hamsters. Psychopharmacol (Berl). 2004;171:298–305. doi:10.1007/s00213-003-1587-7.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Hudson JI, Pope HG. Illicit anabolic–androgenic steroid use. Horm Behav. 2010;58:111–21. doi:10.1016/j.yhbeh.2009.09.006.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, Bhasin S, Pope HG. Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under-recognized problem. Addiction. 2015;110:823–31. doi:10.1111/add.12850.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Hudson JI, Pope HG. Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009;102:130–37. doi:10.1016/j.drugalcdep.2009.02.008.
   PubMed Web of Science ®Google Scholar
• Kritzer M. The distribution of immunoreactivity for intracellular androgen receptors in the cerebral cortex of hormonally intact adult male and female rats: localization in pyramidal neurons making corticocortical connections. Cereb Cortex. 2004;14:268–80. doi:10.1093/cercor/bhg127.
   PubMed Web of Science ®Google Scholar
• Kritzer MF, Creutz LM. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J Neurosci. 2008;28:9525–35. doi:10.1523/JNEUROSCI.2637-08.2008.
   PubMed Web of Science ®Google Scholar
• Low KL, Ma C, Soma KK. Tyramide signal amplification permits immunohistochemical analyses of androgen receptors in the rat prefrontal cortex. J Histochem Cytochem. 2017;65:295–308. doi:10.1369/0022155417694870.
   PubMed Web of Science ®Google Scholar
• Aubele T, Kritzer MF. Gonadectomy and hormone replacement affects in vivo basal extracellular dopamine levels in the prefrontal cortex but not motor cortex of adult male rats. Cereb Cortex. 2011;21:222–32. doi:10.1093/cercor/bhq083.
   PubMed Web of Science ®Google Scholar
• Tobiansky DJ, Wallin-Miller KG, Floresco SB, Wood RI, Soma KK. Androgen regulation of the mesocorticolimbic system and executive function. Front Endocrinol. 2018;9:279. doi:10.3389/fendo.2018.00279.
   PubMed Web of Science ®Google Scholar
• Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097–106. doi:10.1002/cncr.23658.
   PubMed Web of Science ®Google Scholar
• Tan S, Sohrabi HR, Weinborn M, Tegg M, Bucks RS, Taddei K, Carruthers M, Martins RN. Effects of testosterone supplementation on separate cognitive domains in cognitively healthy older men: a meta-analysis of Current randomized clinical trials. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2019;27:1232–46. doi:10.1016/j.jagp.2019.05.008.
   PubMed Web of Science ®Google Scholar
• Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract. 2011;6:44–55. doi:10.1136/bmj.b2495.
   PubMedGoogle Scholar
• Laudet AB, Becker JB, White WL. Don’t wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug Misuse. Subst Use Misuse. 2009;44:227–52. doi:10.1080/10826080802714462.
   PubMed Web of Science ®Google Scholar
• Zhou K, Wang D, Li H, Wei X, Yin J, Liang P, Kou L, Hao M, You L, Li X, et al. Bidirectional relationships between retention and health-related quality of life in Chinese mainland patients receiving methadone maintenance treatment. PLoS ONE. 2017;12:e0179009. doi:10.1371/journal.pone.0179009.
   PubMed Web of Science ®Google Scholar
• Raheem OA, Patel SH, Sisul D, Furnish TJ, Hsieh TC. The role of testosterone supplemental therapy in opioid-induced hypogonadism: a retrospective pilot analysis. Am J Mens Health. 2017;11:1208–13. doi:10.1177/1557988316672396.
   PubMed Web of Science ®Google Scholar
• Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, Eder R, Lakshman K, Bachman E, Mensing G, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280–88. doi:10.1097/01.j.pain.0000460308.86819.aa.
   PubMed Web of Science ®Google Scholar
• Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med Malden Mass. 2012;13:688–98. doi:10.1111/j.1526-4637.2012.01368.x.
   PubMed Web of Science ®Google Scholar
• Aloisi AM, Ceccarelli I, Carlucci M, Suman A, Sindaco G, Mameli S, Paci V, Ravaioli L, Passavanti G, Bachiocco V, et al. Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol RBE. 2011;9:26. doi:10.1186/1477-7827-9-26.
   PubMed Web of Science ®Google Scholar
• Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200–10. doi:10.1016/j.jpain.2005.10.009.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Clark B, Macpherson G, Leppan O, Nielsen S, Zahra E, Larance B, Kimber J, Martino-Burke D, Hickman M, et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 2023;10:386–402. doi:10.1016/S2215-0366(23)00095-0.
   PubMed Web of Science ®Google Scholar
• Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90:203–06. doi:10.1210/jc.2004-0929.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril. 2002;77:936–44. doi:10.1016/S0015-0282(02)02955-2.
   PubMed Web of Science ®Google Scholar
• Limonta P, Wayne Bardin C, Hahn EF, Thau RB. Unexpected effects of nalmefene, a new opiate antagonist, on the hypothalamic-pituitary-gonadal axis in the male rat. Steroids. 1985;46:955–65. doi:10.1016/S0039-128X(85)80003-9.
   PubMed Web of Science ®Google Scholar
• Mello NK, Mendelson JH, Kelly M. Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. Pharmacol Biochem Behav. 2000;66:275–83. doi:10.1016/S0091-3057(00)00190-8.
   PubMed Web of Science ®Google Scholar
• Mendelson JH, Mello NK. Plasma testosterone levels during chronic heroin use and protracted astinence. A study of Hong Kong addicts. Clin Pharmacol Ther. 1975;17:529–33. doi:10.1002/cpt1975175529.
   PubMed Web of Science ®Google Scholar
• Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975;192:211–17.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020;214:108147. doi:10.1016/j.drugalcdep.2020.108147.
   PubMed Web of Science ®Google Scholar
• Santen FJ, Sofsky J, Bilic N, Lippert R. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil Steril. 1975;26:538–48. doi:10.1016/S0015-0282(16)41173-8.
   PubMed Web of Science ®Google Scholar
• Wersocki E, Bedson J, Chen Y, LeResche L, Dunn KM. Comprehensive systematic review of long-term opioids in women with chronic noncancer pain and associated reproductive dysfunction (hypothalamic–pituitary–gonadal axis disruption). PAIN. 2017;158:8. doi:10.1097/j.pain.0000000000000691.
   PubMed Web of Science ®Google Scholar
• Bangasser DA, Valentino RJ. Sex differences in stress-related psychiatric disorders: neurobiological perspectives. Front Neuroendocrinol. 2014;35:303–19. doi:10.1016/j.yfrne.2014.03.008.
   PubMed Web of Science ®Google Scholar
• Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13:859–66. doi:10.1038/nrn3360.
   PubMed Web of Science ®Google Scholar
• Presto P, Mazzitelli M, Junell R, Griffin Z, Neugebauer V. Sex differences in pain along the neuraxis. Neuropharmacology. 2022;210:109030. doi:10.1016/j.neuropharm.2022.109030.
   PubMed Web of Science ®Google Scholar
• Kundakovic M, Rocks D. Sex hormone fluctuation and increased female risk for depression and anxiety disorders: from clinical evidence to molecular mechanisms. Front Neuroendocrinol. 2022;66:101010. doi:10.1016/j.yfrne.2022.101010.
   PubMed Web of Science ®Google Scholar
• Hudson A, Stamp JA. Ovarian hormones and propensity to drug relapse: a review. Neurosci Biobehav Rev. 2011;35:427–36. doi:10.1016/j.neubiorev.2010.05.001.
   PubMed Web of Science ®Google Scholar
• Becker JB, Koob GF, Gottesman MM. Sex differences in animal models: focus on addiction. Pharmacol Rev. 2016 ;68:242–63. doi:10.1124/pr.115.011163.
   PubMed Web of Science ®Google Scholar